1.	Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma Phase: Phase III Type: Treatment Status: Closed Age: 18 to 70 Sponsor: Other Protocol IDs: EORTC-18991, NCT00006249
2.	STI571 ProspectIve RandomIzed Trial: SPIRIT Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 030482, NCT00219739
3.	Phase I/II Study of Pegylated-Interferon Alfa-2a in Previously Untreated Patients with Locally Advanced or Metastatic Renal Cell Carcinoma (Summary Last Modified 07/2000). Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MSKCC-98052, ROCHE-NO15753C, UCLA-9903045, NCI-G98-1475, NCT00003542
4.	Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 2007-0450, NCT00791271
5.	Phase II Study of Pegylated Interferon alfa-2b in Patients With Minimally Treated or Previously Untreated Advanced Low-Grade Non-Hodgkin's Lymphoma (Summary Last Modified 05/2002). Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-99101, NCI-G00-1814, NCT00006039
6.	Phase II Study of Temozolomide and Pegylated Interferon alfa in Patients With Advanced Melanoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-01005, NCI-G01-2031, NCT00027742
7.	A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas Phase: Phase II Type: Treatment Status: Closed Age: 21 and under Sponsor: NCI Protocol IDs: 020193, 02-C-0193, NCI-02-C-0193, NCT00041145, NCT00036569
8.	Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma Phase: Phase II Type: Treatment Status: Closed Age: 21 and under Sponsor: Other Protocol IDs: MEL06, NCT00539591
9.	Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease Phase: No phase specified Type: Biomarker/Laboratory analysis Status: Completed Age: No age specified Sponsor: NCI, Other Protocol IDs: VICC MEL0651, VU-VICC-MEL-0651, VU-VICC-060614, NCT00897312